Healthcare Realty Trust (HR) Financials

Healthcare Realty Trust’s latest results show a business that is generating substantial cash flow while continuing to shrink its asset and debt base. However, reported earnings remain volatile, revenue has declined from 2023 levels, and the company’s very small cash balance leaves limited room for unexpected funding needs.

• Operating cash flow remains consistently positive. Net cash from operating activities was $142.2 million in Q2 2026, following $52.9 million in Q1 2026, $132.3 million in Q4 2025, and $113.8 million in Q3 2025. This suggests the property portfolio continues to produce recurring cash despite GAAP net losses.
• Cash generation substantially exceeds reported net income. Q2 2026 included a $43.9 million net loss, but depreciation and other noncash adjustments helped produce $142.2 million of operating cash flow. This is important for a real estate investment trust, where depreciation can significantly reduce GAAP earnings without directly reducing cash.
• Debt has declined meaningfully over the broader period. Long-term debt fell from approximately $5.57 billion in Q3 2022 to $4.17 billion in Q2 2026. Total liabilities also declined from $6.36 billion to $4.73 billion over the same comparison, improving balance-sheet flexibility.
• Interest expense has generally moved lower. Quarterly interest expense was $46.8 million in Q2 2026, compared with $63.2 million in Q4 2023 and $66.2 million in Q3 2023. The reduction reflects the company’s lower debt balance and may support future cash available for dividends or reinvestment.
• Operating profitability improved from 2023 levels. Total operating income was $39.0 million in Q2 2026, compared with $6.0 million in Q3 2023 and $11.1 million in Q3 2024. Lower selling, general and administrative costs and reduced depreciation expense helped offset weaker revenue.
• Asset sales have been an important source of liquidity. Healthcare Realty generated $59.8 million from property sales in Q2 2026 and $616.3 million in Q4 2025. These transactions have helped fund debt reduction and other capital-allocation priorities.
• Capital spending remains substantial. The company spent $74.3 million on property, plant and equipment in Q2 2026, compared with $63.3 million in Q1 2026 and $86.6 million in Q4 2025. This spending supports the portfolio but reduces cash available for debt repayment and distributions.
• Recent financing activity largely reflects debt management rather than expansion. In Q2 2026, Healthcare Realty issued $738.3 million of debt and repaid $692.5 million, producing only a modest net debt increase before dividends and other financing uses. Investors should monitor whether future issuance is used primarily to refinance maturities or to fund new growth.
• Revenue has trended lower. Operating revenue declined to $281.8 million in Q2 2026 from $297.5 million in Q2 2025, $286.3 million in Q4 2025, and $342.3 million in Q3 2023. The recent improvement in operating income therefore appears to be driven more by cost control and portfolio changes than by top-line growth.
• GAAP earnings remain negative and volatile. Healthcare Realty reported a $43.9 million net loss in Q2 2026, or a $0.13 loss per share, after essentially break-even earnings in Q1 2026 and a $14.6 million profit in Q4 2025. Q2 results were hurt by $39.0 million of net other expense and $46.8 million of interest expense.
• Liquidity is thin relative to the company’s obligations. Cash and equivalents fell to just $19.0 million at June 30, 2026, from $26.2 million at March 31, 2026 and $43.3 million at September 30, 2025. With roughly $4.17 billion of long-term debt, the company remains dependent on operating cash flow, asset sales and access to capital markets.
• Dividend coverage should be watched closely. The company paid $83.3 million of dividends in Q2 2026 against $142.2 million of operating cash flow, but it also spent $74.3 million on property improvements and $76.0 million on share repurchases. The reported dividend per share fell from $0.31 in 2024 and early 2025 to $0.24 in Q4 2025 and Q1 2026, while no dividend-per-share figure was provided for Q2 2026.

Overall, the financial trend is mixed. The most encouraging development is sustained operating cash flow combined with lower debt and interest expense. The principal risks are declining revenue, recurring GAAP losses, very low cash reserves and continued reliance on property sales or refinancing. Investors should focus on recurring cash available for distribution, debt maturities and whether operating performance can stabilize without additional asset sales.